# Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT01496118** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 80 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** panobinostat
- **DRUG:** carfilzomib

## Key facts

- **NCT ID:** NCT01496118
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496118, "Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01496118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*